Which has higher earnings & valuation, SVA or CRBP?

Sinovac Biotech has higher revenue and earnings than Corbus Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $402.82M 0.92 -$59.68M N/A N/A Corbus Pharmaceuticals N/A N/A -$78.54M -$6.19 N/A

Is SVA or CRBP more profitable?

Sinovac Biotech's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Corbus Pharmaceuticals N/A -87.05% -74.22%

Does the media prefer SVA or CRBP?

In the previous week, Corbus Pharmaceuticals had 13 more articles in the media than Sinovac Biotech. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.43 beat Corbus Pharmaceuticals' score of 0.38 indicating that Sinovac Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, MPLT or CRBP?

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maplight Therapeutics N/A N/A -$161.15M -$42.31 N/A Corbus Pharmaceuticals N/A N/A -$78.54M -$6.19 N/A

Is MPLT or CRBP more profitable?

Corbus Pharmaceuticals' return on equity of -87.05% beat Maplight Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Maplight Therapeutics N/A -98.60% -60.33% Corbus Pharmaceuticals N/A -87.05% -74.22%

Does the media favor MPLT or CRBP?

In the previous week, Corbus Pharmaceuticals had 12 more articles in the media than Maplight Therapeutics. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 3 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.93 beat Corbus Pharmaceuticals' score of 0.38 indicating that Maplight Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maplight Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corbus Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is STTK or CRBP more profitable?

Shattuck Labs' return on equity of -43.57% beat Corbus Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Shattuck Labs N/A -43.57% -40.90% Corbus Pharmaceuticals N/A -87.05% -74.22%

Does the media refer more to STTK or CRBP?

In the previous week, Corbus Pharmaceuticals had 12 more articles in the media than Shattuck Labs. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat Corbus Pharmaceuticals' score of 0.38 indicating that Shattuck Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Shattuck Labs 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Corbus Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to VALN or CRBP?

In the previous week, Corbus Pharmaceuticals had 12 more articles in the media than Valneva. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 3 mentions for Valneva. Valneva's average media sentiment score of 0.47 beat Corbus Pharmaceuticals' score of 0.38 indicating that Valneva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Valneva 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Corbus Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Corbus Pharmaceuticals (CRBP) Competitors

$6.92 -1.16 (-14.31%)

As of 03:59 PM Eastern

Compare

CRBP vs. ALT, SVA, MPLT, STTK, and VALN

Should you buy Corbus Pharmaceuticals stock or one of its competitors? Corbus Pharmaceuticals's main competitors and comparable companies include Altimmune (ALT), Sinovac Biotech (SVA), Maplight Therapeutics (MPLT), Shattuck Labs (STTK), and Valneva (VALN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Corbus Pharmaceuticals compare to Altimmune?

Corbus Pharmaceuticals (NASDAQ:CRBP) and Altimmune (NASDAQ:ALT) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings and profitability.

Corbus Pharmaceuticals presently has a consensus price target of $41.00, suggesting a potential upside of 492.14%. Altimmune has a consensus price target of $14.33, suggesting a potential upside of 344.44%. Given Corbus Pharmaceuticals' higher probable upside, equities analysts plainly believe Corbus Pharmaceuticals is more favorable than Altimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
Altimmune	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Corbus Pharmaceuticals had 14 more articles in the media than Altimmune. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 1 mentions for Altimmune. Altimmune's average media sentiment score of 1.17 beat Corbus Pharmaceuticals' score of 0.38 indicating that Altimmune is being referred to more favorably in the news media.

Company	Overall Sentiment
Corbus Pharmaceuticals	Neutral
Altimmune	Positive

64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Altimmune shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Corbus Pharmaceuticals has a beta of 2.63, meaning that its stock price is 163% more volatile than the broader market. Comparatively, Altimmune has a beta of 0.18, meaning that its stock price is 82% less volatile than the broader market.

Corbus Pharmaceuticals has higher earnings, but lower revenue than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A
Altimmune	$31K	20,236.15	-$88.09M	-$0.78	N/A

Corbus Pharmaceuticals has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -31.41% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%
Altimmune	-214,860.98%	-31.41%	-26.96%

Summary

Corbus Pharmaceuticals beats Altimmune on 8 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Sinovac Biotech?

Sinovac Biotech (NASDAQ:SVA) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

In the previous week, Corbus Pharmaceuticals had 13 more articles in the media than Sinovac Biotech. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 2 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.43 beat Corbus Pharmaceuticals' score of 0.38 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Sinovac Biotech has higher revenue and earnings than Corbus Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$402.82M	0.92	-$59.68M	N/A	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

Sinovac Biotech presently has a consensus target price of $1.00, suggesting a potential downside of 84.54%. Corbus Pharmaceuticals has a consensus target price of $41.00, suggesting a potential upside of 492.14%. Given Corbus Pharmaceuticals' higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Sinovac Biotech has a beta of 0.35, suggesting that its stock price is 65% less volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.63, suggesting that its stock price is 163% more volatile than the broader market.

Sinovac Biotech's return on equity of 0.00% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 12.8% of Sinovac Biotech shares are held by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Sinovac Biotech beats Corbus Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Maplight Therapeutics?

Maplight Therapeutics (NASDAQ:MPLT) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

In the previous week, Corbus Pharmaceuticals had 12 more articles in the media than Maplight Therapeutics. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 3 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.93 beat Corbus Pharmaceuticals' score of 0.38 indicating that Maplight Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maplight Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corbus Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 3.8% of Maplight Therapeutics shares are held by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Corbus Pharmaceuticals' return on equity of -87.05% beat Maplight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maplight Therapeutics	N/A	-98.60%	-60.33%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

Maplight Therapeutics currently has a consensus price target of $29.50, indicating a potential upside of 144.51%. Corbus Pharmaceuticals has a consensus price target of $41.00, indicating a potential upside of 492.14%. Given Corbus Pharmaceuticals' higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maplight Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	4 Strong Buy rating(s)	2.94
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maplight Therapeutics	N/A	N/A	-$161.15M	-$42.31	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

Summary

Maplight Therapeutics beats Corbus Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Shattuck Labs?

Shattuck Labs (NASDAQ:STTK) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, media sentiment, valuation and risk.

In the previous week, Corbus Pharmaceuticals had 12 more articles in the media than Shattuck Labs. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 3 mentions for Shattuck Labs. Shattuck Labs' average media sentiment score of 1.69 beat Corbus Pharmaceuticals' score of 0.38 indicating that Shattuck Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Shattuck Labs	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Corbus Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Shattuck Labs has higher revenue and earnings than Corbus Pharmaceuticals. Shattuck Labs is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Shattuck Labs	$1M	599.67	-$48.81M	-$0.51	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

58.7% of Shattuck Labs shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 8.8% of Shattuck Labs shares are owned by insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Shattuck Labs currently has a consensus target price of $12.78, suggesting a potential upside of 113.85%. Corbus Pharmaceuticals has a consensus target price of $41.00, suggesting a potential upside of 492.14%. Given Corbus Pharmaceuticals' higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than Shattuck Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Shattuck Labs	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Shattuck Labs' return on equity of -43.57% beat Corbus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Shattuck Labs	N/A	-43.57%	-40.90%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

Shattuck Labs has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.63, meaning that its share price is 163% more volatile than the broader market.

Summary

Shattuck Labs beats Corbus Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Corbus Pharmaceuticals compare to Valneva?

Valneva (NASDAQ:VALN) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation and media sentiment.

Corbus Pharmaceuticals has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Corbus Pharmaceuticals' return on equity of -87.05% beat Valneva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Valneva	-110.33%	-153.20%	-39.50%
Corbus Pharmaceuticals	N/A	-87.05%	-74.22%

Valneva has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Corbus Pharmaceuticals has a beta of 2.63, indicating that its stock price is 163% more volatile than the broader market.

In the previous week, Corbus Pharmaceuticals had 12 more articles in the media than Valneva. MarketBeat recorded 15 mentions for Corbus Pharmaceuticals and 3 mentions for Valneva. Valneva's average media sentiment score of 0.47 beat Corbus Pharmaceuticals' score of 0.38 indicating that Valneva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Valneva	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corbus Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Corbus Pharmaceuticals has lower revenue, but higher earnings than Valneva. Valneva is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valneva	$142.94M	4.35	-$130.33M	-$2.11	N/A
Corbus Pharmaceuticals	N/A	N/A	-$78.54M	-$6.19	N/A

11.4% of Valneva shares are owned by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 3.5% of Corbus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valneva presently has a consensus price target of $9.30, suggesting a potential upside of 41.98%. Corbus Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 492.14%. Given Corbus Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Corbus Pharmaceuticals is more favorable than Valneva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valneva	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67
Corbus Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Corbus Pharmaceuticals beats Valneva on 10 of the 15 factors compared between the two stocks.

Get Corbus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRBP vs. The Competition

Export

Metric	Corbus Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$129.36M	$3.82B	$7.17B	$14.35B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	-1.12	14.23	273.42	25.33
Price / Sales	N/A	1,539.83	674.50	98.17
Price / Cash	N/A	43.64	28.42	34.96
Price / Book	0.82	15.24	10.40	6.21
Net Income	-$78.54M	-$22.78M	$3.49B	$358.18M
7 Day Performance	-34.68%	-2.52%	-2.06%	-1.50%
1 Month Performance	-31.38%	0.31%	-0.29%	-3.52%
1 Year Performance	-26.10%	38.80%	19.04%	5.93%

Corbus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRBP Corbus Pharmaceuticals	3.3087 of 5 stars	$6.92 -14.3%	$41.00 +492.1%	-14.9%	$129.36M	N/A	N/A	40	Trending News Analyst Forecast Options Volume High Trading Volume
ALT Altimmune	2.5402 of 5 stars	$3.29 -1.8%	$14.33 +335.7%	-9.3%	$651.63M	$40K	N/A	50
SVA Sinovac Biotech	1.0905 of 5 stars	$6.47 flat	$1.00 -84.5%	N/A	$644.66M	$386.01M	N/A	3,008	High Trading Volume
MPLT Maplight Therapeutics	2.8372 of 5 stars	$13.78 +0.5%	$29.50 +114.1%	N/A	$635.84M	N/A	N/A	109
STTK Shattuck Labs	3.6416 of 5 stars	$6.15 -2.8%	$12.78 +107.8%	+222.9%	$635.30M	$1M	N/A	100	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRBP) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. ALT, SVA, MPLT, STTK, and VALN

How does Corbus Pharmaceuticals compare to Altimmune?

Summary

How does Corbus Pharmaceuticals compare to Sinovac Biotech?

Summary

How does Corbus Pharmaceuticals compare to Maplight Therapeutics?

Summary

How does Corbus Pharmaceuticals compare to Shattuck Labs?

Summary

How does Corbus Pharmaceuticals compare to Valneva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corbus Pharmaceuticals (CRBP) Competitors

CRBP vs. ALT, SVA, MPLT, STTK, and VALN

How does Corbus Pharmaceuticals compare to Altimmune?

Do analysts prefer CRBP or ALT?

Does the media refer more to CRBP or ALT?

Do institutionals & insiders hold more shares of CRBP or ALT?

Which has more risk and volatility, CRBP or ALT?

Which has stronger valuation & earnings, CRBP or ALT?

Is CRBP or ALT more profitable?

Summary

How does Corbus Pharmaceuticals compare to Sinovac Biotech?

Does the media prefer SVA or CRBP?

Which has higher earnings & valuation, SVA or CRBP?

Do analysts recommend SVA or CRBP?

Which has more volatility & risk, SVA or CRBP?

Is SVA or CRBP more profitable?

Do insiders & institutionals hold more shares of SVA or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Maplight Therapeutics?

Does the media favor MPLT or CRBP?

Do insiders and institutionals hold more shares of MPLT or CRBP?

Is MPLT or CRBP more profitable?

Do analysts recommend MPLT or CRBP?

Which has preferable valuation & earnings, MPLT or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Shattuck Labs?

Does the media refer more to STTK or CRBP?

Which has preferable earnings & valuation, STTK or CRBP?

Do insiders & institutionals hold more shares of STTK or CRBP?

Do analysts rate STTK or CRBP?

Is STTK or CRBP more profitable?

Which has more risk and volatility, STTK or CRBP?

Summary

How does Corbus Pharmaceuticals compare to Valneva?

Is VALN or CRBP more profitable?

Which has more risk and volatility, VALN or CRBP?

Does the media refer more to VALN or CRBP?

Which has stronger valuation and earnings, VALN or CRBP?

Do institutionals and insiders have more ownership in VALN or CRBP?

Do analysts recommend VALN or CRBP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRBP vs. The Competition

Corbus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools